Artiness Achieves FDA 510(k) Clearance for Articor Planner Through Strategic Regulatory Collaboration with NAMSA
Client Background
Artiness is an Italy-based software company specializing in innovative solutions for interventional cardiology, with a focus on structural heart interventions. Founded in 2018 and headquartered in Milan, Artiness is dedicated to advancing clinical decision-making through an innovative software platform that bridges the gap between medical imaging and real-world procedural execution with real-time navigation.
ARTICOR Planner represents the first step in this broader technological vision: the software enables clinicians to analyze patient anatomy, select and size devices, plan delivery strategies, and optimize procedural approaches using 3D reconstructions derived from DICOM-compliant medical images. These models can be further visualized within an augmented reality environment, enabling enhanced spatial understanding and supporting more informed decision-making for transcatheter cardiovascular interventions.
As a startup pioneering the application of augmented and mixed-reality technologies in cardiovascular care, Artiness set out to bring ARTICOR Planner to the U.S. market through FDA 510(k) clearance, marking its first engagement with a major regulatory authority and a critical milestone in its commercialization strategy.
Project Scope
Artiness partnered with NAMSA to support the preparation and submission of an FDA 510(k) application for its ARTICOR Planner software, with the goal of enabling U.S. market entry for this novel pre-procedural planning solution. Artiness faced several critical challenges as it pursued FDA 510(k) clearance for ARTICOR Planner:
- Limited prior experience interacting with regulatory authorities in both the U.S. and Europe
- The need to define and validate a robust regulatory pathway for a novel, mixed-reality–enabled software solution
- Managing FDA expectations for a technology with limited precedent in the market
- Ensuring submission readiness while minimizing regulatory risk
As a first-time applicant, Artiness required not only technical support but also strategic guidance across the entire regulatory journey, from pathway definition to final submission.
The Solution
NAMSA partnered closely with Artiness to provide end-to-end regulatory support, combining strategic expertise with hands-on collaboration.
Regulatory Strategy & Submission Readiness
NAMSA supported Artiness in refining its regulatory strategy, including:
- Confirming and strengthening predicate device selection
- Identifying additional testing aligned with international standards
- Conducting a gap assessment of submission documentation to reduce regulatory risk
This proactive approach ensured alignment with FDA expectations early in the process and helped de-risk the submission.
Collaborative Documentation & Review
Artiness led the preparation of core documentation, while NAMSA provided:
- Detailed review and technical feedback
- Structured templates to improve clarity and consistency of responses
- Guidance on how to position information effectively for FDA reviewers
This highly collaborative workflow enabled efficient iteration and ensured that all materials met regulatory standards.
FDA Interaction & Deficiency Management
Following FDA review, NAMSA and Artiness worked together to address additional information requests:
- Rapid engagement with FDA within the designated response window to clarify deficiencies
- Strategic framing of questions and responses to ensure alignment with FDA expectations
- Preparation of structured response packages to streamline review
NAMSA also provided critical support during FDA interactions, helping Artiness interpret feedback and respond effectively in a highly technical regulatory environment.
The Outcome
Through a highly coordinated and collaborative effort, Artiness successfully achieved FDA 510(k) clearance for its ARTICOR Planner software, marking a significant milestone in the company’s path toward U.S. market entry and broader adoption of its innovative technology.
A standout achievement of this project was the timing of the clearance, which was granted ahead of the expected regulatory deadline. The FDA completed its review and issued clearance approximately nine days before the due date, without requesting additional rounds of questions, an outcome that is uncommon in the 510(k) process, particularly for first-time submitters and innovative technologies.
This accelerated outcome was driven by several key factors:
- High-quality submission documentation, developed through a rigorous and iterative process
- Proactive engagement with FDA, including timely clarification of deficiencies and structured responses to additional information requests
- Effective regulatory strategy, including validated predicate selection and alignment with Agency expectations
- Strong collaboration across all stakeholders, including Artiness, NAMSA, and FDA
Beyond achieving clearance, the engagement also delivered broader value for Artiness:
- Established a robust regulatory foundation for future product development and expanded indications
- Validated a regulatory pathway for innovative mixed-reality–based technologies in cardiovascular care
- Positioned Artiness as an emerging innovator in pre-procedural planning and image-guided interventions
Ultimately, the success of this project demonstrates how early strategic alignment, high-quality documentation, and close collaboration between client, regulatory partner, and Agency can significantly streamline the path to market, even for novel technologies.
FDA Clearance Achieved
FDA Follow-up Questions
Days to Clearance
At ARTINESS, we have been pleased by the senior and professional advisory of NAMSA, making the process controlled and smooth and ensuring that our innovative software could reach such an incredible achievement.
Filippo Piatti, CEO & Co-FounderMeet Our FDA Regulatory Experts
Explore the depth of our expertise in FDA consulting.
Related Services That May Interest You
FDA 510(k) Consultants
FDA Pre-Sub and Q-Sub Consulting
